Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for Tobacco Dependence
- PMID: 20682457
- PMCID: PMC2947623
- DOI: 10.1016/j.pscychresns.2009.06.004
Smoking-induced change in intrasynaptic dopamine concentration: effect of treatment for Tobacco Dependence
Abstract
The aim of this study was to determine whether standard treatments for Tobacco Dependence affect smoking-induced changes in intrasynaptic dopamine (DA) concentration. Forty-three otherwise healthy adult cigarette smokers (10 to 40 cigarettes per day) were treated with either practical group counseling (PGC) psychotherapy (n=14), bupropion HCl (n=14), or matching pill placebo (n=15) (random assignment) for 8 weeks. Before and after treatment, each subject underwent a bolus-plus-continuous-infusion (11)C-raclopride positron emission tomography (PET) scanning session, during which he or she smoked a regular cigarette. The PET scanning outcome measure of interest was percent change in smoking-induced (11)C-raclopride binding potential (BP(ND)) in the ventral caudate/nucleus accumbens (VCD/NAc), as an indirect measure of DA release. Although the entire study sample had a smaller mean smoking-induced reduction in VCD/NAc BP(ND) after treatment (compared to before treatment), this change was highly correlated with smaller total cigarette puff volumes (and not other treatment variables). These data indicate that smoking-induced DA release is dose-dependent, and is not significantly affected by reductions in daily smoking levels or treatment type.
Published by Elsevier Ireland Ltd.
Figures
Similar articles
-
Negative association of pretreatment cigarette use with smoking-induced striatal dopamine release in smokers receiving bupropion treatment.Am J Addict. 2016 Sep;25(6):486-92. doi: 10.1111/ajad.12419. Epub 2016 Jul 28. Am J Addict. 2016. PMID: 27467186
-
Ventral striatal dopamine release in response to smoking a regular vs a denicotinized cigarette.Neuropsychopharmacology. 2009 Jan;34(2):282-9. doi: 10.1038/npp.2008.87. Epub 2008 Jun 18. Neuropsychopharmacology. 2009. PMID: 18563061 Free PMC article. Clinical Trial.
-
Smoking-induced ventral striatum dopamine release.Am J Psychiatry. 2004 Jul;161(7):1211-8. doi: 10.1176/appi.ajp.161.7.1211. Am J Psychiatry. 2004. PMID: 15229053
-
Use of sustained-release bupropion in specific patient populations for smoking cessation.Drugs. 2002;62 Suppl 2:37-43. doi: 10.2165/00003495-200262002-00004. Drugs. 2002. PMID: 12109934 Review.
-
Bupropion: risks and benefits.Expert Opin Drug Saf. 2005 Nov;4(6):995-1003. doi: 10.1517/14740338.4.6.995. Expert Opin Drug Saf. 2005. PMID: 16255659 Review.
Cited by
-
Methods for Quantifying Neurotransmitter Dynamics in the Living Brain With PET Imaging.Front Physiol. 2020 Jul 21;11:792. doi: 10.3389/fphys.2020.00792. eCollection 2020. Front Physiol. 2020. PMID: 32792972 Free PMC article. Review.
-
Elevation of dopamine induced by cigarette smoking: novel insights from a [11C]-+-PHNO PET study in humans.Neuropsychopharmacology. 2014 Jan;39(2):415-24. doi: 10.1038/npp.2013.209. Epub 2013 Aug 19. Neuropsychopharmacology. 2014. PMID: 23954846 Free PMC article.
-
Denicotinized versus average nicotine tobacco cigarette smoking differentially releases striatal dopamine.Nicotine Tob Res. 2013 Jan;15(1):11-21. doi: 10.1093/ntr/nts029. Epub 2012 Apr 5. Nicotine Tob Res. 2013. PMID: 22491891 Free PMC article.
-
The Relationship of Varenicline Agonism of α4β2 Nicotinic Acetylcholine Receptors and Nicotine-Induced Dopamine Release in Nicotine-Dependent Humans.Nicotine Tob Res. 2020 May 26;22(6):892-899. doi: 10.1093/ntr/ntz080. Nicotine Tob Res. 2020. PMID: 31096265 Free PMC article. Clinical Trial.
-
Influence of Nicotine Metabolism Ratio on [11C]-(+)-PHNO PET Binding in Tobacco Smokers.Int J Neuropsychopharmacol. 2018 Jun 1;21(6):503-512. doi: 10.1093/ijnp/pyx119. Int J Neuropsychopharmacol. 2018. PMID: 29346545 Free PMC article.
References
-
- Abrams DB, Niaura RS, Brown RA, Emmons KM, Goldstein MG, Monti PM. The Tobacco Dependence Treatment Handbook: A Guide to Best Practices. The Guilford Press; 2003.
-
- Amini F, Lewis T, Lannon R, Louie A, Baumbacher G, McGuinness T, Schiff EZ. Affect, attachment, memory: contributions toward psychobiologic integration. Psychiatry. 1996;59:213–239. - PubMed
-
- Argyelan M, Szabo Z, Kanyo B, Tanacs A, Kovacs Z, Janka Z, Pavics L. Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study. Journal of Affective Disorders. 2005;89:115–123. - PubMed
-
- Ascher JA, Cole JO, Colin JN, Feighner JP, Ferris RM, Fibiger HC, Golden RN, Martin P, Potter WZ, Richelson E, Sulser F. Bupropion: a review of its mechanism of antidepressant activity. Journal of Clinical Psychiatry. 1995;56:395–401. - PubMed
-
- Balfour DJ. The pharmacology underlying pharmacotherapy for tobacco dependence: A focus on bupropion. International Journal of Clinical Practice. 2001;55:53–57. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources